About us Contacts Drug interactions: 390 212
Drug search by name

Tenecteplase and Xigris

Determining the interaction of Tenecteplase and Xigris and the possibility of their joint administration.

Check result:
Tenecteplase <> Xigris
Relevance: 14.03.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

If you are currently receiving or have recently received tenecteplase within the past 3 days, you should talk to your doctor before getting treatment with drotrecogin alfa. Combining these medications can increase the risk of serious or life-threatening bleeding complications. If treatment with the combination is required, you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Let your doctor know promptly if you experience any unusual bleeding or bruising, swelling, vomiting, blood in your urine or stools, headache, dizziness, or weakness during treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: Concurrent administration of thrombolytic agents and drotrecogin alfa may increase the risk of serious or life-threatening bleeding complications due to additive or synergistic effects on the clotting cascade. Drotrecogin alfa inactivates blood clotting Factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin times (PT).

MANAGEMENT: When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.

References
  • "Product Information. Xigris (drotrecogin alfa)." Lilly, Eli and Company, Indianapolis, IN.
Tenecteplase

Generic Name: tenecteplase

Brand name: TNKase

Synonyms: n.a.

Xigris

Generic Name: drotrecogin alfa

Brand name:

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction